You are here: Industry Insights > Boehringer Ingelheim

News List

Boehringer Ingelheim makes its best molecules available to the scientific community europeanpharmaceuticalreview
November 22, 2017
Boehringer Ingelheim has announced the launch of a new platform offering free and open access to selected pre-clinical molecules for a non-clinical investigation to scientists worldwide…
Boehringer Ingelheim and MiNA Therapeutics to develop novel treatment approaches for fibrotic liver worldpharmanews
November 10, 2017
MiNA Therapeutics ("MiNA"), pioneer of Boehringer Ingelheim and RNA-activated therapies, has signed an agreement and a license agreement
IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to 'listen for the sounds o worldpharmanews
September 20, 2017
IPF is a progressive and debilitating disease which causes continual and irreversible damage to the lungs.(1) Early diagnosis is vital because without appropriate medical intervention, the opportunity to slow disease progression is lost.
EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting po fiercepharma
September 14, 2017
Meanwhile, after unveiling its own cardiovascular outcomes data at ADA, rival Johnson & Johnson will have subanalyses of its own to present later in the week.
With FDA’s Approval of the Second Biosimilar, Humira to Fight for the Glory of King! en-cphi.cn
September 01, 2017
There comes the second FDA-approved biosimilar of AbbVie’s branded drug Humira (adalimumab), as the tumor necrosis factor (TNF) blocker Cyltezo of Boehringer Ingelheim was approved for marketing by FDA on August 25.
Boehringer Ingelheim Receives FDA Approval for Cyltezo americanpharmaceuticalreview
August 31, 2017
Boehringer Ingelheim announced the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases
Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating l worldpharmanews
August 28, 2017
Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335, acquired from Pharmaxis in May 2015
Boehringer Ingelheim Initiates Phase IIa Study of Compound Acquired from Pharmaxis americanpharmaceuticalreview
August 25, 2017
Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015.
Sanofi shakes up agency team, adding WPP Group to media and creative partners fiercepharma
August 22, 2017
To handle the creative side of its Sanofi business win, WPP plans to form an international Team Sanofi division.
Sales of Boehringer Ingelheim's prescription drugs jump 12 percent in first half firstwordpharma
August 03, 2017
Boehringer Ingelheim said Wednesday that sales of prescription medicines climbed 12 percent in the first half of the year to 6.1 billion euros ($7.2 billion), boosted by the company's diabetes portfolio and the of idiopathic pulmonary fibrosis treatment O

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page